DIAGNOSIS OF ENDOCRINE DISEASE: Bone turnover markers: are they clinically useful?

Bone Turnover Markers: Use in Fracture Prediction

(2017) Tatiane Vilaca et al.   JOURNAL OF CLINICAL DENSITOMETRY

Response to Letter: Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation

(2017) Olivier Lamy et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates

(2017) A. Diez-Perez et al.   OSTEOPOROSIS INTERNATIONAL

Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability

(2017) P. Szulc et al.   OSTEOPOROSIS INTERNATIONAL

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis

(2016) Paul D. Miller et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis

(2016) Kosuke Ebina et al.   JOURNAL OF BONE AND MINERAL METABOLISM

Potential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women With Osteoporosis: Secondary Analysis of Randomized Controlled Trial Data

(2016) Katy JL Bell et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Urinary N-telopeptide and Rate of Bone Loss Over the Menopause Transition and Early Postmenopause

(2016) Albert Shieh et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

(2016) P. D. Miller et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A retrospective analysis of nonresponse to daily teriparatide treatment

(2016) R. Niimi et al.   OSTEOPOROSIS INTERNATIONAL

Association of bone turnover markers with volumetric bone loss, periosteal apposition, and fracture risk in older men and women: the AGES-Reykjavik longitudinal study

(2016) E. A. Marques et al.   OSTEOPOROSIS INTERNATIONAL

Response of bone turnover markers to raloxifene treatment in postmenopausal women with osteopenia

(2016) K. E. Naylor et al.   OSTEOPOROSIS INTERNATIONAL

Postmenopausal osteoporosis

(2016) Richard Eastell et al.   Nature Reviews Disease Primers

Relationship Between Pretreatment Rate of Bone Loss and Bone Density Response to Once-Yearly ZOL: HORIZON-PFT Extension Study

(2015) Richard Eastell et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)

(2015) Dennis M. Black et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Are Biochemical Markers of Bone Turnover Representative of Bone Histomorphometry in 370 Postmenopausal Women?

(2015) Pascale Chavassieux et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

(2015) S. Papapoulos et al.   OSTEOPOROSIS INTERNATIONAL

Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study

(2015) K. E. Naylor et al.   OSTEOPOROSIS INTERNATIONAL

A Meta-Analysis of Reference Markers of Bone Turnover for Prediction of Fracture

(2014) Helena Johansson et al.   CALCIFIED TISSUE INTERNATIONAL

PINP as a biological response marker during teriparatide treatment for osteoporosis

(2014) J. H. Krege et al.   OSTEOPOROSIS INTERNATIONAL

Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy

(2014) Douglas C. Bauer et al.   JAMA Internal Medicine

BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate

(2013) Brian Louis McNabb et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Risk Factors for Treatment Failure With Antiosteoporosis Medication: The Global Longitudinal Study of Osteoporosis in Women (GLOW)

(2013) Adolfo Díez-Pérez et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Adherence to raloxifene therapy: assessment methods and relationship with efficacy

(2013) J. Finigan et al.   OSTEOPOROSIS INTERNATIONAL

An algorithm using the early changes in PINP to predict the future BMD response for patients treated with daily teriparatide

(2013) R. Niimi et al.   OSTEOPOROSIS INTERNATIONAL

Reference intervals of bone turnover markers in healthy premenopausal women: Results from a cross-sectional European study

(2012) Richard Eastell et al.   BONE

Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition)

(2012) Yoshiki Nishizawa et al.   JOURNAL OF BONE AND MINERAL METABOLISM

Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT)

(2012) Richard M Jacques et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Treatment failure in osteoporosis

(2012) A. Diez-Perez et al.   OSTEOPOROSIS INTERNATIONAL

Official Positions for FRAX® Clinical Regarding Biochemical Markers

(2011) Eugene V. McCloskey et al.   JOURNAL OF CLINICAL DENSITOMETRY

PINP as an aid for monitoring patients treated with teriparatide

(2010) Mika Tsujimoto et al.   BONE

Status of Hemoglobin A1c Measurement and Goals for Improvement: From Chaos to Order for Improving Diabetes Care

(2010) R. R. Little et al.   CLINICAL CHEMISTRY

Effects of denosumab on bone turnover markers in postmenopausal osteoporosis

(2010) Richard Eastell et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards

(2010) S. Vasikaran et al.   OSTEOPOROSIS INTERNATIONAL

Adherence and profile of non-persistence in patients treated for osteoporosis—a large-scale, long-term retrospective study in The Netherlands

(2010) J. C. Netelenbos et al.   OSTEOPOROSIS INTERNATIONAL

Rapid and robust response of biochemical markers of bone formation to teriparatide therapy

(2009) Sarah J. Glover et al.   BONE

Effects of Yearly Zoledronic Acid 5 mg on Bone Turnover Markers and Relation of PINP With Fracture Reduction in Postmenopausal Women With Osteoporosis

(2009) Pierre D Delmas et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Establishing a reference range for bone turnover markers in young, healthy women

(2008) S.J. Glover et al.   BONE

Establishing a Reference Interval for Bone Turnover Markers in 637 Healthy, Young, Premenopausal Women From the United Kingdom, France, Belgium, and the United States

(2008) Sarah J Glover et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Serial Assessment of Serum Bone Metabolism Markers Identifies Women with the Highest Rate of Bone Loss and Osteoporosis Risk

(2008) Kaisa K. Ivaska et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM